DOCSLIB.ORG

Free PDF Download

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Free PDF Download European Review for Medical and Pharmacological Sciences 2019; 23: 9681-9690 New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard S. ZAAMI Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Rome, Italy Abstract. – OBJECTIVE: New psychoactive Introduction substances (NPS), are a range of drugs de- signed to mimic the effects of established illic- New psychoactive substances (NPS) are a it drugs, being legal at the time of their distribu- range of drugs that are designed, manufactured tion in illicit markets. The review aims to shed a light on the growing threat caused by NPS, and and marketed to replicate the effects of illegal on the dynamics and developments that have established substances (e.g., cannabis, cocaine, led to their spread, including the risk of new ecstasy and LSD1). At the time of their arrival adulteration practices which can cause a seri- on street and web markets, such substances are ous health threat, due to their increased toxicity, mostly not scheduled under the 1961 Single Con- e.g., through fentanyl and its analogs. vention on Narcotic Drugs or the 1971 Conven- MATERIALS AND METHODS: An overview of statistical trends relative to NPS use has been tion on Psychotropic Substances. Manufacturers provided, in addition to regulatory and legisla- of these drugs deliberately develop new chemi- tive approaches in several countries and recom- cals to replace others that have been banned. In mendations and data from International institu- this concern, NPS chemical structures constantly tions: UN Office on Drugs and Crime, United Na- change and develop in an attempt to stay ahead of tions Commission on Narcotic Drugs, WHO, Eu- ropean Parliament, European Monitoring Centre the national and international banning laws, and for Drugs and Drug Addiction, Europol and inter- when a new substance is scheduled a new ana- national collaborative efforts such as the Trans log is created to restart the process of distribut- European Drug Information (TEDI) project and ing a free psychotropic substance. Over the past the Spanish Energy Control. decade, the emergence of hundreds of NPS has RESULTS: Given the elusive nature of NPS, represented a daunting challenge for public health spontaneous pharmacovigilance reporting sys- tems are needed to identify new trends of drug and drug policies on a global scale. Such drugs abuse. Broad-ranging legislative initiatives are are relatively new to recreational drug markets, needed in order to set common international and the definition encompasses all NPS, as well standards (e.g., the European Parliament Reg- as drugs that even though not newly synthesized, ulation 2017/2101, with information exchange, have recently seen a significant rise in terms of il- an early warning system and risk assessment legal use2,3. NPS may be categorized by chemical procedure for NPS) to tackle a potentially cata- strophic and growing threat. structure, psychoactive properties, biological tar- 4 CONCLUSIONS: By virtue of all the complex- gets, or by source (plant, synthetic, or combined ), ities and hurdles that have to be overcome in and can be subdivided into four main categories: the fight against NPS, and to assist national governments in their identification and report- • Synthetic cannabinoids – they mimic the can- ing, supranational organizations can come to play a key role. Only through international mea- nabis effects and are traded under various sures, supplementing national legislative initia- “street names”. They show no chemical rela- tives, can this multi-faceted problem be effec- tion to delta-9-tetrahydrocannabinol, the psy- tively addressed and information about NPS be choactive principle of cannabis, but they act on gathered and disseminated in a timely fashion. cannabinoid brain receptors in a similar way to Key Words: that of cannabis. New psychoactive substances, Adulteration, Drug • Stimulant-type drugs – they simulate the psy- of abuse, Legislative measures. choactive effects of substances such as am- Corresponding Author: Simona Zaami, MD; e-mail: simona.zaami@uniroma1.it 9681 S. Zaami phetamine, cocaine and ecstasy and include phenomenon that has to be highlighted is given compounds such as e.g., benzylpiperazine, by the evidence that the most recent NPS started synthetic cathinones (e.g., mephedrone), meth- to be targeted to a different type of consumers, ylphenidate and analogs, methylenedioxypy- thus transitioning from being substances for rec- rovalerone, 5,6-methylenedioxy-2-aminoin- reational weekend music parties and casual sex- dane, ethylphenidate. New benzodiazepines ual scenes to narcotic and depressant substances and tranquilisers (a.k.a., ‘Downer’/tranquilis- aimed at chronic heroin users, namely new syn- er-type drugs), which are designed to repli- thetic opioids and new benzodiazepines9-11. cate the effects of tranquilisers or anti-anxiety drugs, especially from the benzodiazepine family, including, among others, etizolam, pyr- Lawmakers and regulatory bodies azolam and flubromazepam. strive to keep up • Hallucinogenic drugs – these drugs simulate the central action of substances like lysergic The European new psychoactive substances acid diethylamide and include the substances (NPS) market has increased at a somewhat alarm- of 2-C phenetylamines (2-CB, 2-CE, 2C-I), ing rate, to such an extent that established drug ketamine, deschloro-N-ethyl-ketamine. control laws have struggled to keep up. Several countries have therefore devised and enacted new legal responses to this phenomenon, either based Broad-ranging variety only adds to on existing laws (mostly focused on consumer or the problem health protection or pharmaceuticals), or by pass- ing new and innovative pieces of legislation. As of NPS, sometimes incorrectly called “legal 2018, over 60 countries have implemented legal highs”, are being developed at an unprecedented responses to control NPS, many of which resorted rate since the beginning of the century. The two to the existing legislation, sometimes properly years which registered the highest number of NPS amended, while others decided to draw up and seized in the European Union have been 2014 and enact innovative legal instruments. Several Euro- 20155. In this concern, as of December 2015, a pean and non-European countries (Austria, Den- total of 643 new psychoactive substances were mark, France, Hungary, Hong Kong, Ireland, Is- reported in the United Nations Office of Drugs rael, Japan, Lithuania, Norway, the Russian and Crime (UNODC) Early Warning Advisory Federation, Switzerland, the United Arab Emir- on NPS6. The emergence of 75 NPS was reported ates, the United Kingdom and the United States12), for the first time in 2015, most of them belonging where a large number of different NPS has rapid- to synthetic cannabinoids (which act as Synthet- ly emerged, have adopted controls on entire sub- ic Cannabinoid Receptor Agonists, 21), synthetic stance groups of NPS using a so-called generic cathinones (β-keto phenethylamines and chemi- approach, or have introduced analogue legislation cally similar to amphetamine and methamphet- that invokes the principle of “chemical similarity” amine, 20) and phenethylamines (most of which to an already controlled substance in order to con- act as either central nervous system stimulants, or trol substances not explicitly mentioned in the as hallucinogens, 9), in addition to 21 more, that legislation. Legislation regulating known NPS are structurally diverse and do not belong to any varies internationally. In Germany, a draft law of the above mentioned groups7. After those two was adopted by the government in May 2016, to years, the yearly number of reported substances be eventually enacted by parliament in September started to decrease, mainly due to the fact that of the same year. Under this draft law, NPS are banning laws imposed more severe and specific defined as any substance or preparation which be- restrictions to the classes of prohibited psychotro- longs to a specified generic group definitions for pic drugs and to the seizing action of police forces. synthetic cannabinoids and compounds derived Nevertheless, by the end of 2018, the EMCDDA from 2-phenylethylamine. It should be noted how- was monitoring more than 730 new psychoactive ever that substances that are already listed in the substances, 55 of which were detected for the first Narcotics Act or Medicines Act have been ex- time in Europe in 2018. These include synthetic empted. Based on expert advice, the German cannabinoids, stimulants (including cathinones), Health Ministry has the authority to amend or up- hallucinogens and opioids that are designed to date such definitions. Manufacturing, trading, mimic the effects of established substances8. A importing, possessing and offering NPS is unlaw- 9682 NPS: concerted efforts and common legislative answers for stemming a growing health hazard ful under the legislation; law enforcement agen- necessary in order to prevent their distribution cies are entitled to confiscate and dispose of such and avoid ensuing health hazards. Two conditions substances, by virtue of their authority to protect must be fulfilled for any substance to fall within life and health. Customs officials may confiscate that definition: (1): it can be assumed that they substances that they have good reason to believe will be distributed for the purpose of being mis- are potentially harmful NPS. As for offences aris- used by
Load more

Recommended publications
  • Differentiation and Identification of Fentanyl Analogues Using GC-IRD
    Forensic Chemistry 20 (2020) 100255 Contents lists available at ScienceDirect Forensic Chemistry journal homepage: www.elsevier.com/locate/forc Diferentiation and identifcation of fentanyl analogues using GC-IRD T ⁎ ⁎ Agnes D. Winokura, , Lindsay M. Kaufmana, Jose R. Almirallb, a DEA Southeast Laboratory, Miami, FL, USA b Department of Chemistry and Biochemistry and Center for Advanced Research in Forensic Science (CARFS), Florida International University, Miami, FL, USA HIGHLIGHTS • Demonstration of the diferentiation and identifcation of fentanyls using GC-IRD. • Optimization of GC-IRD parameters including chromatographic and spectral acquisition. • Reporting of limitations in sensitivity for casework samples. • Case study description involving the use of GC-IRD for analysis of a polydrug mixture. ARTICLE INFO ABSTRACT Keywords: Fentanyl analogues and their positional isomers have similar chemical structural confgurations making them GC-IRD difcult to identify and diferentiate. Gas chromatography coupled to a gas-phase infrared detector (GC-IRD) is a Fentanyl analogues useful and powerful tool for the unambiguous identifcation of fentanyl compounds where traditional analytical PTV techniques such as gas chromatography–mass spectrometry (GC–MS) ofer limited information for this class of Light pipe compounds. In this study, we demonstrate the utility of GC-IRD and show how this complementary information Positional isomers enables the identifcation of fentanyl analogues (2- and 3- furanylfentanyl, 2-furanylbenzylfentanyl, croto- nylfentanyl, cyclopropylfentanyl, methoxyacetylfentanyl, carfentanil, meta-fuoroisobutyryl fentanyl, para- fuoroisobutyryl fentanyl and ortho-fuoroisobutyryl fentanyl) when combined with GC–MS data. A description of the operating conditions including how the optimization of GC-IRD parameters can enhance the spectral resolution and unambiguous identifcation of these fentanyl analogues is presented, for the frst time.
    [Show full text]
  • English Advance Version of the CND Report
    E/2020/28 E/CN.7/2020/15 United Nations Commission on Narcotic Drugs Report on the sixty-third session (13 December 2019 and 2–6 March 2020) Economic and Social Council Official Records, 2020 Supplement No. 8 Economic and Social Council E/2020/28 Official Records, 2020 E/CN.7/2020/15 Supplement No. 8 Commission on Narcotic Drugs Report on the sixty-third session (13 December 2019 and2–6 March 2020) United Nations • New York, 2020 E/2020/28 E/CN.7/2020/15 Note Symbols of United Nations documents are composed of letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. The report of the Commission on Narcotic Drugs on its reconvened sixty-third session, to be held on 3 and 4 December 2020, will be issued as Official Records of the Economic and Social Council, 2020, Supplement No. 8A (E/2020/28/Add.1). ISSN 0251-9941 E/2020/28 E/CN.7/2020/15 [23 March 2020] Contents Chapter Page Executive summary ......................................................... vi I. Matters calling for action by the Economic and Social Council or brought to its attention 1 A. Draft decisions for adoption by the Economic and Social Council ............... 1 I. Report of the Commission on Narcotic Drugs on its sixty-third session and provisional agenda for its sixty-fourth session ........................... 1 II. Report of the International Narcotics Control Board ...................... 2 B. Matters brought to the attention of the Economic and Social Council ............ 2 Resolution 63/1 Promoting efforts by Member States to address and counter the world drug problem, in particular supply reduction-related measures, through effective partnerships with private sector entities ..............................................
    [Show full text]
  • WHO Expert Committee on Drug Dependence
    WHO Technical Report Series 1034 This report presents the recommendations of the forty-third Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the International Drug Control Conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD advises the Director-General of WHO to reschedule or to amend the scheduling status of a substance. The Director-General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs. This report summarizes the findings of the forty-third meeting at which the Committee reviewed 11 psychoactive substances: – 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) WHO Expert Committee – 3-Fluorophenmetrazine (3-FPM) – 3-Methoxyphencyclidine (3-MeO-PCP) on Drug Dependence – Diphenidine – 2-Methoxydiphenidine (2-MeO-DIPHENIDINE) Forty-third report – Isotonitazene – MDMB-4en-PINACA – CUMYL-PEGACLONE – Flubromazolam – Clonazolam – Diclazepam The report also contains the critical review documents that informed recommendations made by the ECDD regarding international control of those substances. The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.
    [Show full text]
  • GHB, GBL & Related Compounds: Literature Review
    ACMD Advisory Council on the Misuse of Drugs An assessment of the harms of gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and closely related compounds November 2020 1 Contents 1. Introduction ................................................................................................................................... 4 2. Previous ACMD advice and legal status of GHBRS- UK ..................................................... 5 3. Chemistry and pharmacology ................................................................................................... 7 GHB ................................................................................................................................................... 7 GBL.................................................................................................................................................... 8 1,4-BD ............................................................................................................................................... 8 GHV/GVL .......................................................................................................................................... 9 4. Therapeutic and other legitimate uses of GHBRS ............................................................... 10 Therapeutic uses ........................................................................................................................... 10 Industrial/commercial uses .........................................................................................................
    [Show full text]
  • Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
    Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves.
    [Show full text]
  • Critical Review Report: CROTONYLFENTANYL
    Critical Review Report: CROTONYLFENTANYL Expert Committee on Drug Dependence Forty-second Meeting Geneva, 21-25 October 2019 This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 42nd ECDD (2019): Crotonylfentanyl © World Health Organization 2019 All rights reserved. nd This is an advance copy distributed to the participants of the 42 Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • Infographics About Synthetic Opioids
    UNODC LEADING THE INTERGRATED GLOBAL RESPONSE TO THE OPIOID CRISIS P I L L A R 1 P I L L A R 2 P I L L A R 3 P I L L A R 4 P I L L A R 5 I N T E R N A T I O N A L L A W S T R E N G T H E N I N G C O U N T E R E A R L Y W A R N I N G A N D R A T I O N A L P R E S C R I B I N G A N D S T R E N G T H E N I N G A N D S U P P O R T I N G E N F O R C E M E N T O P E R A T I O N S N A R C O T I C C A P A C I T Y A N D T R E N D A N A L Y S I S A C C E S S T O O P I O I D S P R E V E N T I O N A N D T R E A T M E N T T O D I S R U P T T R A F F I C K I N G I N T E R N A T I O N A L C O O P E R A T I O N IDENTIFYING THE MOST PREVELANT, PERSISTANT AND HARMFUL SYNTHETIC OPIOIDS U N O D C 282 90 E A R L Y TOXICOLOGY COLLABORATING IN COUNTRIES W A R N I N G INFORMED THREATS LABORATORIES A D V I S O R Y ASSESSMENTS PHARMACOLOGICAL INFORMATION L A B O R A T O R I E S A N D D A T A P O I N T S L A B O R A T O R I E S D A T A P O I N T S G L O B A L S M A R T U P D A T E S 21,400+ 120 DATA POINTS FROM COUNTRIES SYNTHETIC SEDATIVE 74 OPIOIDS HYPNOTICS REPORTED MIRRORING TO UNODC SYNTHETIC E A R L Y OPIOID TRENDS W A R N I N G A D V I S O R Y B Y 2019 131% IN THE LAST * * 3 Y E A R S Note: * 2019 data collection not finalized LIST OF SYNTHETIC OPIOIDS REPORTED TO THE UNODC EWA FROM 2009-2019 S C H E D U L E D 2-Fluorofentanyl Furanylfentanyl 4-Fluorobutyrfentanyl Methoxyacetylfentanyl 4-Fluoroisobutyrfentanyl MT-45 S C H E D U L E I Acrylfentanyl Ocfentanil ( 1 9 6 1 ) AH-7921 Tetrahydrofuranylfentanyl Butyrfentanyl U-47700 S C H E D U L E I & I V Cyclopropylfentanyl
    [Show full text]
  • Substances Recommended to Be Added to Schedule I of the Single Convention on Narcotic Drugs (1961), As Amended by the 1972 Protocol
    Annex 1: Summary of the rationale for the recommendations of the 42nd Expert Committee on Drug Dependence Substances recommended to be added to Schedule I of the Single Convention on Narcotic Drugs (1961), as amended by the 1972 Protocol: Crotonylfentanyl The chemical name for crotonylfentanyl is (2E)-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]but-2- enamide. Crotonylfentanyl binds to mu opioid receptors and acts as an opioid agonist. In animal models, crotonylfentanyl produces antinociception, actions predictive of oxycodone-like subjective effects and both central nervous system stimulation and depression. The opioid antagonist naltrexone blocks the effects of crotonylfentanyl. This pharmacological profile indicates that crotonylfentanyl is an opioid and comparative studies suggest that it has a potency intermediate between oxycodone and fentanyl. Consistent with the results from animal studies, the effects of crotonylfentanyl were reversed by an opioid antagonist in a clinical admission due to overdose. Due to its opioid mechanism of action, crotonylfentanyl has the potential to be associated with substantial harm. Crotonylfentanyl has been found in seized material from countries across several regions. It has no veterinary or medical use. Based on its opioid mechanism of action and similarity to drugs such as oxycodone and fentanyl that are controlled under Schedule I of the Single Convention on Narcotic Drugs, it is recommended that crotonylfentanyl also be controlled under Schedule I of the Single Convention on Narcotic Drugs (1961). Valerylfentanyl The chemical name for valerylfentanyl is N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]pentanamide. Valerylfentanyl binds to mu opioid receptors and acts as an opioid agonist.
    [Show full text]
  • LC Paper No. CB(2)929/20-21(04)
    LC Paper No. CB(2)929/20-21(04) For discussion on 9 April 2021 Legislative Council Panel on Security Proposed Amendments to the First Schedule to the Dangerous Drugs Ordinance and Schedule 2 to the Control of Chemicals Ordinance PURPOSE This paper seeks Members’ views on the Government’s proposal to – (a) bring eight dangerous drugs, namely 4F-MDMB-BINACA 1 , 5F-AMB-PINACA 2 , 5F-MDMB-PICA 3 , crotonylfentanyl, etizolam, flualprazolam, mitragynine and 7-hydroxymitragynine, under control in Part I of the First Schedule to the Dangerous Drugs Ordinance (“DDO”) (Cap. 134); and (b) bring one precursor chemical, namely methyl alpha- phenylacetoacetate (“MAPA”), under control in Schedule 2 to the Control of Chemicals Ordinance (“CCO”) (Cap. 145). JUSTIFICATIONS 2. As a regular exercise, the Government has from time to time proposed amendments to DDO and CCO as appropriate to include new substances under statutory control, having regard to a host of relevant factors, including international control requirements, the uses and harmful effects of the substances, severity of abuse in the local and overseas contexts, advice of the Action Committee Against Narcotics (“ACAN”) and relevant authorities, etc. This is to ensure that law enforcement agencies in Hong Kong could respond effectively to the latest drug developments. 1 Also known as 4F-MDMB-BUTINACA. 2 Also known as 5F-AMB and 5F-MMB-PINACA. 3 Also known as 5F-MDMB-2201. Eight Dangerous Drugs Six Substances under International Control 3. At the 63rd Session of the United Nations Commission on Narcotic Drugs (“UNCND”) held in March 2020, Member States adopted the recommendation by the World Health Organisation (“WHO”) to place 12 dangerous drugs under international control.
    [Show full text]
  • Addressing Synthetic and Designer Drugs in Adult Drug Courts By: Blaine Stum
    A Challenging Design: Addressing Synthetic and Designer Drugs in Adult Drug Courts By: Blaine Stum American University - Justice Programs Office is a technical assistance provider for the BJA Adult Drug Court Program. This fact sheet is part of a series created to respond to significant issues identified during the provision of technical assistance to the field. For more information about accessing technical assistance services or to learn more about the AU Justice Programs Office, go to www.american.edu/justice. Synthetic Drugs - Substances wherein the psychoactive properties of a scheduled drug have been retained, but the molecular structure has been altered in order to avoid prosecution under the Controlled Substances Act. - D.E. Smith and R.B. Seymour, 1985 Introduction Legal Status Over the last decade, the prevalence of synthetic and Currently, there are two laws that specifically address designer drugs has increased at alarming rates. The synthetic or designer drugs: European Monitoring Centre for Drugs and Addiction identified 13 new psychoactive substances (NPSs) in 1. The Federal Analogue Act (21 U.S.C. § 813) 2008 and 98 NPSs in 2015, a 653% increase in only 7 2. The Synthetic Drug Abuse Prevention Act (21 years.i A total of 480 NPSs were identified during U.S.C. 812(c)) that time frame. The Federal Analogue Act was passed by Congress in 1986. The bill amended the Controlled Substances Act (21 U.S.C. §801 et. Seq) so that synthetic or designer drugs that are “substantially similar” to drugs already on Schedule I or II are treated the same as those con- trolled substances.ii The Synthetic Drug Abuse Prevention Act was passed by Congress in 2012.
    [Show full text]
  • United Nations
    E/2020/28 E/CN.7/2020/15 United Nations Commission on Narcotic Drugs Report on the sixty-third session (13 December 2019 and 2–6 March 2020) Economic and Social Council Official Records, 2020 Supplement No. 8 V.20-01956 (E) *2001956* Economic and Social Council E/2020/28 Official Records, 2020 E/CN.7/2020/15 Supplement No. 8 Commission on Narcotic Drugs Report on the sixty-third session (13 December 2019 and2–6 March 2020) United Nations • New York, 2020 E/2020/28 E/CN.7/2020/15 Note Symbols of United Nations documents are composed of letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. The report of the Commission on Narcotic Drugs on its reconvened sixty-third session, to be held on 3 and 4 December 2020, will be issued as Official Records of the Economic and Social Council, 2020, Supplement No. 8A (E/2020/28/Add.1). ISSN 0251-9941 E/2020/28 E/CN.7/2020/15 [23 March 2020] Contents Chapter Page Executive summary ......................................................... vi I. Matters calling for action by the Economic and Social Council or brought to its attention 1 A. Draft decisions for adoption by the Economic and Social Council ............... 1 I. Report of the Commission on Narcotic Drugs on its sixty-third session and provisional agenda for its sixty-fourth session ........................... 1 II. Report of the International Narcotics Control Board ...................... 2 B. Matters brought to the attention of the Economic and Social Council ............ 2 Resolution 63/1 Promoting efforts by Member States to address and counter the world drug problem, in particular supply reduction-related measures, through effective partnerships with private sector entities ..............................................
    [Show full text]
  • Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis
    molecules Article Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis Piotr F. J. Lipi ´nski 1,* , Piotr Kosson 2, Joanna Matali ´nska 1, Piotr Roszkowski 3, Zbigniew Czarnocki 3, Małgorzata Jaro ´nczyk 4 , Aleksandra Misicka 1,3 , Jan Cz. Dobrowolski 4 and Joanna Sadlej 4,5,* 1 Department of Neuropeptides, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland; jmatalinska@imdik.pan.pl (J.M.); misicka@imdik.pan.pl (A.M.) 2 Toxicology Research Laboratory, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland; pkosson@imdik.pan.pl 3 Faculty of Chemistry, University of Warsaw, 02-093 Warsaw, Poland; roszkowski@chem.uw.edu.pl (P.R.); czarnoz@chem.uw.edu.pl (Z.C.); misicka@chem.uw.edu.pl (A.M.) 4 National Medicines Institute, 00-725 Warsaw, Poland; m.jaronczyk@nil.gov.pl (M.J.); j.dobrowolski@nil.gov.pl (J.Cz.D.) 5 Faculty of Mathematics and Natural Sciences, University of Cardinal Stefan Wyszy´nski,1/3 Wóycickiego-Str., 01-938 Warsaw, Poland * Correspondence: plipinski@imdik.pan.pl (P.F.J.L.); j.sadlej@uksw.edu.pl (J.S.) Received: 30 January 2019; Accepted: 15 February 2019; Published: 19 February 2019 Abstract: Interactions of 21 fentanyl derivatives with µ-opioid receptor (µOR) were studied using experimental and theoretical methods. Their binding to µOR was assessed with radioligand competitive binding assay. A uniform set of binding affinity data contains values for two novel and one previously uncharacterized derivative. The data confirms trends known so far and thanks to their uniformity, they facilitate further comparisons.
    [Show full text]